Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Back in Black for Second Quarter

Affymetrix today reported net income of $5.2 million on revenues of $68.6 million for the second quarter ending June 30, compared to a loss of $1.6 million on revenues of $71 million for the second quarter 2002 and a turnaround from its first quarter net loss of $12.7 million on revenues of $67 million.

 

The company attributed the gains to record instrument revenue of $15.6 million on top of revenues of $30 million from sales of its GeneChip brand arrays. Wafer sales to Perlegen Sciences accounted for $2.8 million, compared to $5.6 million for the same period a year ago.

 

Affymetrix reported R&D expenses of $16.6 million for the quarter, compared to $17.3 million for the year-ago quarter.

 

The company reported cash and cash equivalents of $37 million on June 30, compared to $68 million on Dec. 31, 2002.

 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.